SCHEMBL8099548

SCHEMBL8099548

COc1cccc(N2CCN(C(=O)C3CCCCC3C(=O)NC3(N)CC3)CC2)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 10/20 0.68
▸ CTSB P07858 9/20 0.60
▸ CTSS P25774 9/20 0.60
▸ KMT2A Q03164 3/20 0.53
▸ MEN1 O00255 2/20 0.53
▸ ADAM10 O14672 1/20 0.53
▸ ERBB2 P04626 1/20 0.53
▸ MMP2 P08253 1/20 0.53
▸ KCNH2 Q12809 1/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ CA12 O43570 2/20 0.48
▸ CA1 P00915 2/20 0.48
▸ CA2 P00918 2/20 0.48
▸ CA9 Q16790 2/20 0.48
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.46
▸ GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8110520 0.84 CTSK (0.64) CTSKCTSBCTSSADAM10ERBB2
SCHEMBL8110058 0.77 CTSK (0.56) CTSKCTSBCTSSADAM10ERBB2
SCHEMBL8107799 0.74 CTSK (0.55) CTSKCTSBCTSS
SCHEMBL8107396 0.74 CTSK (1.00) CTSKCTSBCTSSKCNH2CYP3A4
SCHEMBL8099434 0.74 CTSK (0.54) CTSKCTSBCTSS
SCHEMBL3109916 0.72 KMT2A (0.61) CTSKKMT2AMEN1SMN1; SMN2CA12
SCHEMBL3103835 0.72 KMT2A (0.61) CTSKKMT2AMEN1SMN1; SMN2CA12
SCHEMBL8108928 0.72 CTSK (0.52) CTSKCTSBCTSSFFAR4
SCHEMBL8110145 0.72 HRH3 (0.50) CTSKCTSBCTSSKMT2AMEN1
SCHEMBL8113972 0.72 CTSK (0.48) CTSKCTSBCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009001127-A1 CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS ASTRAZENECA AB (SE) 2008-12-31 — — WO disclosed
Send feedback